Gonadal Organoids Rebalance HPG Axis via Chorionic Gonadotrophin

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for rebalancing the hypothalamic-pituitary-gonadal (HPG) axis are insufficient, leading to partial rebalancing with increased risks of neoplasia and vascular issues, as they rely on supplemental hormone addition rather than comprehensive axis rebalancing.

Innovation Solution

The creation of gonadal organoids composed of major cell types such as Sertoli, Leydig, and endothelial cells for testicular function, and granulosa, oocytes, and thecal cells for ovarian function, which are introduced into subjects with periodic chorionic gonadotrophin (CG) administration to maintain hormone balance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If supplemental hormone addition is used to rebalance the HPG axis, then hormone levels are restored, but risks of neoplasia and vascular issues increase

Engineering Contradiction:

ImproveHPG axis rebalancing effectivenessVSAvoidrisks of neoplasia and vascular issues

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces gonadal organoids as intermediary structures that naturally produce hormones in response to CG administration. These organoids act as mediators between the administered CG and the HPG axis, enabling physiological hormone production rather than direct hormone supplementation, thereby reducing the harmful effects associated with exogenous hormone therapy

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The gonadal organoids are designed to autonomously produce hormones in response to CG stimulation, eliminating the need for direct hormone supplementation. The organoids self-regulate hormone production based on physiological needs, mimicking natural gonadal function and avoiding the risks associated with external hormone administration

Inventive Principle:

Principle #25Self-service

2Quantity of substance

If partial rebalancing is achieved through current methods, then some hormone levels improve, but comprehensive axis rebalancing fails and neoplasia risk increases

Engineering Contradiction:

Improvehormone levelsVSAvoidcomprehensive axis rebalancing

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The gonadal organoids are designed to perform multiple functions simultaneously: producing multiple different hormones (testosterone, estrogen, progesterone, inhibin), responding to CG stimulation, and regulating their own activity through feedback mechanisms. This multi-functionality enables comprehensive HPG axis rebalancing rather than partial correction of individual hormone levels

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent utilizes parameter changes in CG administration (dosage, frequency, timing) to regulate the activity of gonadal organoids, thereby controlling hormone production levels. By adjusting these parameters, comprehensive rebalancing of multiple hormone levels can be achieved simultaneously while avoiding the neoplasia risks associated with fixed-dose hormone supplementation

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20230058240A1Methods of generating hormone-producing organoids and reversing hypogonadism

Publication Date: 2023.02.23 ATWOOD CRAIG S

AI summary

A method of improving integration and/or functionality of gonadal organoids introduced to a subject includes the steps of pre-treating the subject with a chorionic gonadotrophin (CG), administering a therapeutically effective amount of the gonadal organoids to the subject, and administering the CG to the subject over time post-treatment to maintain LHCG receptor expression and signaling.